863491-70-7

Basic information

• Product Name: C₄₂H₃₇FN₄O₄
• CAS NO: 863491-70-7
• Molecular Weight: 680.779
• Mol File: 863491-70-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₄₂H₃₇FN₄O₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₄₂H₃₇FN₄O₄(863491-70-7)
• EPA Substance Registry System: C₄₂H₃₇FN₄O₄(863491-70-7)

Safety Data

• Hazardous Substances Data: 863491-70-7(Hazardous Substances Data)

Usage

General Description

C42H37FN4O4 is the chemical formula for fluoxetine, which is a selective serotonin reuptake inhibitor (SSRI) used to treat depression, panic disorder, and other mood disorders. The molecular structure of fluoxetine contains 42 carbon atoms, 37 hydrogen atoms, 1 fluorine atom, 4 nitrogen atoms, and 4 oxygen atoms. Its chemical composition and the arrangement of its atoms give fluoxetine its pharmacological properties, allowing it to effectively regulate serotonin levels in the brain and alleviate symptoms of depression and anxiety.

Upstream product

• 140-75-0 para-fluorobenzylamine 
• 84174-25-4 p-fluorobenzylamine formamide 
• 405-66-3 (4-Fluoro-benzyl)-methyl-amine 
• 863492-35-7 2-amino-quinoline-6-carboxylic acid benzyl ester 
• 863492-33-5 quinoline-6-carboxylic acid benzyl Ester 
• 10349-57-2 Quinoline-6-carboxylic acid 

Downstream Products

• 1356917-05-9 C₄₃H₃₉FN₄O₅ 

Relevant articles and documents

Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide

Analogues related to dirlotapide (1), a gut-selective inhibitor of microsomal triglyceride transfer protein (MTP) were prepared with the goal of further reducing the potential for unwanted liver MTP inhibition and associated side-effects. Compounds were designed to decrease active metabolite load: reducing MTP activity of likely human metabolites and increasing metabolite clearance to reduce exposure. Introduction of 4′-alkyl and 4′-alkoxy substituents afforded compounds exhibiting improved therapeutic index in rats with respect to liver triglyceride accumulation and enzyme elevation. Likely human metabolites of select compounds were prepared and characterized for their potential to inhibit MTP in vivo. Based on preclinical efficacy and safety data and its potential for producing short-lived, weakly active metabolites, compound 13 (PF-02575799) advanced into phase 1 clinical studies.